Patents Assigned to Apeiron Biologics AG
-
Publication number: 20240158530Abstract: The present invention relates to preparations and methods for treating a GD2 positive cancer by administering a preparation comprising a chimeric or humanized anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2wherein a GD2 positive cancer is treated in the patient. Furthermore, the invention relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein a preparation comprising an anti-GD2 antibody is administered to the patient as a continuous infusion, without concomitantly administering IL-2. The present invention further relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein the one or more anti-GD2 antibody treatment periods is/are preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.Type: ApplicationFiled: March 6, 2023Publication date: May 16, 2024Applicant: APEIRON BIOLOGICS AGInventors: Hans LOIBNER, Oliver MUTSCHLECHNER, Ruth LADENSTEIN, Isabel KLIER
-
Publication number: 20230340148Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.Type: ApplicationFiled: September 19, 2022Publication date: October 26, 2023Applicant: APEIRON BIOLOGICS AGInventors: Hans LOIBNER, Manfred SCHUSTER, Evelyne JANZEK-HAWLAT, Susanne WIEDERKUM, Bernhard PEBALL, Stefan STRANNER, Oliver MUTSCHLECHNER, Franz GROISS, Ruth LADENSTEIN, Holger LODE
-
Patent number: 11597775Abstract: The present invention relates to preparations and methods for treating a GD2 positive cancer by administering a preparation comprising a chimeric or humanized anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2 wherein a GD2 positive cancer is treated in the patient. Furthermore, the invention relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein a preparation comprising an anti-GD2 antibody is administered to the patient as a continuous infusion, without concomitantly administering IL-2. The present invention further relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein the one or more anti-GD2 antibody treatment periods is/are preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.Type: GrantFiled: November 28, 2017Date of Patent: March 7, 2023Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Oliver Mutschlechner, Ruth Ladenstein, Isabel Klier
-
Patent number: 11492412Abstract: A method of treating a high-risk neuroblastoma in a patient is described.Type: GrantFiled: March 3, 2021Date of Patent: November 8, 2022Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Oliver Mutschlechner, Ruth Ladenstein, Isabel Klier
-
Patent number: 11447565Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.Type: GrantFiled: September 11, 2017Date of Patent: September 20, 2022Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Manfred Schuster, Evelyne Janzek-Hawlat, Susanne Wiederkum, Bernhard Peball, Stefan Stranner, Oliver Mutschlechner, Franz Groiss, Ruth Ladenstein, Holger Lode
-
Publication number: 20210221909Abstract: A method of treating a high-risk neuroblastoma in a patient is described.Type: ApplicationFiled: March 3, 2021Publication date: July 22, 2021Applicant: APEIRON BIOLOGICS AGInventors: Hans LOIBNER, Oliver MUTSCHLECHNER, Ruth LADENSTEIN, Isabel KLIER
-
Patent number: 10995147Abstract: A method of treating a high-risk neuroblastoma in a patient is described.Type: GrantFiled: July 6, 2020Date of Patent: May 4, 2021Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Oliver Mutschlechner, Ruth Ladenstein, Isabel Klier
-
Publication number: 20200332021Abstract: A method of treating a high-risk neuroblastoma in a patient is described.Type: ApplicationFiled: July 6, 2020Publication date: October 22, 2020Applicant: APEIRON BIOLOGICS AGInventors: Hans LOIBNER, Oliver MUTSCHLECHNER, Ruth LADENSTEIN, Isabel KLIER
-
Patent number: 10716833Abstract: The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life.Type: GrantFiled: December 6, 2017Date of Patent: July 21, 2020Assignee: APEIRON BIOLOGICS AGInventors: Manfred Schuster, Hans Loibner, Evelyne Janzek-Hawlat, Bernhard Peball, Stefan Stranner, Bettina Wagner, Robert Weik
-
Patent number: 10472341Abstract: The present invention relates to bicyclic tetrahydrothiazepine of formula (I), wherein R1 to R3, X1, X2 and R18 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising such compounds as well as their use as medicaments, especially in methods for the treatment or prevention of a neoplastic and/or infectious disease and in vitro methods.Type: GrantFiled: February 29, 2016Date of Patent: November 12, 2019Assignees: APEIRON BIOLOGICS AG, EVOTEC SEInventors: Monika Ermann, Guenther Lametschwandtner, Patricia Leonie Amouzegh, Russell Stuart Craft, Thomas Hanke, Timothy Robin James, Severine Danielle Jones, Hans Loibner, Pui Leng Loke, Ina Sternberger, Anton Stuetz, Roland Wehr, Mark Whittaker
-
Patent number: 10294305Abstract: Preparations and methods for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2), and wherein one or more treatment periods with the antibody may be preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.Type: GrantFiled: February 18, 2014Date of Patent: May 21, 2019Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Oliver Mutschlechner, Ruth Ladenstein, Isabel Klier
-
Publication number: 20180258183Abstract: The present invention relates to preparations and methods for treating a GD2 positive cancer by administering a preparation comprising a chimeric or humanized anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2 wherein a GD2 positive cancer is treated in the patient. Furthermore, the invention relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein a preparation comprising an anti-GD2 antibody is administered to the patient as a continuous infusion, without concomitantly administering IL-2. The present invention further relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein the one or more anti-GD2 antibody treatment periods is/are preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.Type: ApplicationFiled: November 28, 2017Publication date: September 13, 2018Applicant: APEIRON BIOLOGICS AGInventors: Hans LOIBNER, Oliver MUTSCHLECHNER, Ruth LADENSTEIN, Isabel KLIER
-
Publication number: 20180134801Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.Type: ApplicationFiled: September 11, 2017Publication date: May 17, 2018Applicant: APEIRON BIOLOGICS AGInventors: Hans LOIBNER, Manfred SCHUSTER, Evelyne JANZEK-HAWLAT, Susanne WIEDERKUM, Bernhard PEBALL, Stefan STRANNER, Oliver MUTSCHLECHNER, Franz GROISS, Ruth LADENSTEIN, Holger LODE
-
Patent number: 9840566Abstract: The present invention relates to preparations and methods for treating a GD2 positive cancer by administering a preparation comprising a chimeric or humanized anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with interleukin-2 (IL-2 wherein a GD2 positive cancer is treated in the patient. Furthermore, the invention relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein a preparation comprising an anti-GD2 antibody is administered to the patient as a continuous infusion, without concomitantly administering IL-2. The present invention further relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein the one or more anti-GD2 antibody treatment periods is/are preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.Type: GrantFiled: November 21, 2014Date of Patent: December 12, 2017Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Oliver Mutschlechner, Ruth Ladenstein, Isabel Klier
-
Patent number: 9777068Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.Type: GrantFiled: July 31, 2012Date of Patent: October 3, 2017Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Manfred Schuster, Evelyne Janzek-Hawlat, Susanne Wiederkum, Bernhard Peball, Stefan Stranner, Oliver Mutschlechner, Franz Groiss, Ruth Ladenstein, Holger Lode
-
Patent number: 9561263Abstract: The present invention relates to ACE2 for the therapeutic treatment or prevention of inflammation.Type: GrantFiled: December 18, 2008Date of Patent: February 7, 2017Assignee: Apeiron Biologics AGInventors: Hans Loibner, Manfred Schuster
-
Publication number: 20160304620Abstract: The present invention relates to preparations and methods for treating a GD2 positive cancer by administering a preparation comprising a chimeric or humanized anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with interleukin-2 (IL-2 wherein a GD2 positive cancer is treated in the patient. Furthermore, the invention relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein a preparation comprising an anti-GD2 antibody is administered to the patient as a continuous infusion, without concomitantly administering IL-2. The present invention further relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein the one or more anti-GD2 antibody treatment periods is/are preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.Type: ApplicationFiled: November 21, 2014Publication date: October 20, 2016Applicant: APEIRON BIOLOGICS AGInventors: Hans LOIBNER, Oliver MUTSCHLECHNER, Ruth LADENSTEIN, Isabel KLIER
-
Patent number: 9186373Abstract: The invention relates to a method for the immune activation of NK cells by the reduction or inhibition of the Cbl-b function in said cells. This stimulates the congenital immune system and thus permits the therapy of appropriate diseases.Type: GrantFiled: December 27, 2011Date of Patent: November 17, 2015Assignee: Apeiron Biologics AGInventors: Günther Lametschwandtner, Hans Loibner, Manfred Schuster, Isabella Haslinger, Sandra Seidl
-
Publication number: 20150313931Abstract: The invention relates to a method for the immune activation of NK cells by the reduction or inhibition of the Cbl-b function in said cells. This stimulates the congenital immune system and thus permits the therapy of appropriate diseases.Type: ApplicationFiled: July 16, 2015Publication date: November 5, 2015Applicant: APEIRON BIOLOGICS AGInventors: Gunther Lametschwandtner, Hans Loibner, Manfred Schuster, Isabella Haslinger, Sandra Seidl
-
Publication number: 20150139942Abstract: The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.Type: ApplicationFiled: July 31, 2012Publication date: May 21, 2015Applicant: APEIRON BIOLOGICS AGInventors: Hans Loibner, Manfred Schuster, Evelyne Janzek-Hawlat, Susanne Wiederkum, Bernhard Peball, Stefan Stranner, Oliver Mutschlechner, Franz Groiss, Ruth Ladenstein, Holger Lode